Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
03:30pm, Thursday, 08'th Sep 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
05:30am, Monday, 05'th Sep 2022 GlobeNewswire Inc.
Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Des données de dernière minute sur Dupixent® (dupilumab) présentées au congrès de l’ERS 2022 montrent un profil de sécurité et d’efficacité homogène pendant une durée pouvant atteindre
Communiqué de presse: Evolution au sein du Conseil d’Administration
05:00am, Monday, 05'th Sep 2022 GlobeNewswire Inc.
Evolution au sein du Conseil d’Administration
Press Release: Evolution of the Board of Directors
05:00am, Monday, 05'th Sep 2022 GlobeNewswire Inc.
Evolution of the Board of Directors
Communiqué de presse: XenpozymeTM (olipudase alfa-rpcp) approuvé par la FDA – premier médicament indiqué expressément pour le traitement des manifestations non neurologiques du déficit en sphingomyélinase acide
06:30pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
XenpozymeTM (olipudase alfa-rpcp) approuvé par la FDA – premier médicament indiqué expressément pour le traitement des manifestations non neurologiques du déficit en sphingomyélinase acide
Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
06:30pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A
05:30am, Tuesday, 30'th Aug 2022 GlobeNewswire Inc.
FDA grants priority review to efanesoctocog alfa for people with hemophilia A
Communiqué de presse: La FDA accorde un examen prioritaire à l’efanesoctocog alpha pour le traitement de l’hémophilie A
05:30am, Tuesday, 30'th Aug 2022 GlobeNewswire Inc.
La FDA accorde un examen prioritaire à l’efanesoctocog alpha pour le traitement de l’hémophilie A
Ray Dalio's Bridgewater cuts European short bet to under $1 billion
04:46am, Thursday, 18'th Aug 2022
Bridgewater Associates, one of the biggest hedge funds in the world, has seemingly walked away from its big short bet
Press Release: Sanofi provides update on amcenestrant clinical development program
05:30am, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
Sanofi provides update on amcenestrant clinical development program
Communiqué de presse: Sanofi fait le point sur le programme de développement clinique de l’amcenestrant
05:30am, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
Sanofi fait le point sur le programme de développement clinique de l’amcenestrant
GSK defends Zantac ahead of trials that have wiped off $44 billion from leading drugmakers
07:24pm, Friday, 12'th Aug 2022 MarketWatch
GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation f
Here's Why Rocket Is Taking Steps to Diversify Its Business
09:48am, Friday, 12'th Aug 2022 The Motley Fool
While the mortgage origination business struggles, Rocket is increasing its wallet share with other products
Here's Why Rocket Is Taking Steps to Diversify Its Business
05:48am, Friday, 12'th Aug 2022
While the mortgage origination business struggles, Rocket is increasing its wallet share with other products
